Amgenʼs Biologics Story

Expanding our global patient reach.

Amgen Biosimilars is committed to building upon Amgen’s experience in the development and manufacturing of innovative human therapeutics to expand our reach to patients suffering from serious illnesses. Biosimilars offer the potential to increase patient access to vital medicines and Amgen is well positioned to leverage its more than 35 years of experience in biotechnology to create high-quality biosimilars and reliably supply them to patients worldwide.


Amgen’s mission is to serve patients, especially those suffering from serious illness. We currently have a robust pipeline with several biosimilar molecules in development which target some of the most complex and important oncology and inflammation antibody biologics. With decades of experience and world-class scientific expertise, we are applying scientific innovation to drive the research and development of biosimilars and address some of healthcare’s most pressing challenges to improve the lives of patients. Building from Amgen’s successful track record, we will strive to make Amgen Biosimilars reliably available to patients and we will continue to make investments to support Amgen’s mission.

Positioned for Success
The story of Amgen began more than 35 years ago thanks to a handful of scientists and investors who believed in the promise of innovative biotechnology. Since that time, our commitment to innovation has led to the launch of cutting-edge therapies and deep biologics manufacturing expertise to help patients battling serious illness—and Amgen Biosimilars is a continuation of this tradition. Our mission to serve patients is a constant source of inspiration for our scientists, whether they are working to characterize key biologic processes or to develop or manufacture a biosimilar medicine.

Biotechnology provides sophisticated ways to attack disease and Amgen was among the first companies to develop therapeutic proteins, which can replace or augment beneficial human proteins, and monoclonal antibodies, allowing our medicines to strike disease targets with enhanced precision. Our success in this area is reflected in our product portfolio, which includes novel therapies for hard-to-treat diseases. These therapies have been used to treat millions of patients and with the growth of Amgen’s biosimilars portfolio, there is an opportunity to treat many more. 

Our commitment to innovation inspires us to engineer new types of therapeutic platforms, including biosimilars. As we forge ahead, Amgen Biosimilars will add new chapters to our story, realizing the hope that these newly available biotechnology medicines will bring to patients around the world.



Amgen - Bringing the Power of Medicine to Patients for More than 35 Years


BIOLOGICS        SMALL MOLECULE

Erythropoietin Stimulating Agent GLYCOPROTEIN

1989

Granulocyte Colony Stimulating Factor PROTEIN

1991

Anti-Tumor Necrosis Factor Alpha1FUSION PROTEIN

1998

Methionyl Human Stem Cell Factor2 PROTEIN

1999

Long Lasting Erythropoietin Stimulating Agent GLYCOPROTEIN

 

Interleukin-1 Receptor Antagonist2 PROTEIN

2001

Long-Acting Granulocyte Colony Stimulating Factor PEG-CONJUGATED PROTEIN

2002

Calcimimetic CHEMICAL COMPOUND

 

Keratinocyte Growth Factor2 PROTEIN

2004

Pan-Kinase Inhibitor3 CHEMICAL COMPOUND

2005

Anti-Epidermal Growth Factor Receptor HUMAN MONOCLONAL ANTIBODY

2006

Thrombopoietin Mimetic PEPTIDE FUSION

2008

Anti-Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)HUMAN MONOCLONAL ANTIBODY

 

Anti-Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)HUMAN MONOCLONAL ANTIBODY

2010

Proteasome Inhibitor3 CHEMICAL COMPOUND

2012

Anti-CD19 Bispecific T Cell Engager (BiTE®) BISPECIFIC ANTIBODY FRAGMENT

2014

1.  Acquired from Immunex in 2002
2.  Sold to Biovitrum in 2008
3.  Acquired from Onyx in 2013